Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01296763 · ClinicalTrials.gov registry record · Phase 1
Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01296763 is a Phase 1 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 18 participants.
The verdict
NCT01296763, a Phase 1 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
Patients whose pancreatic cancers have defects in the BRCA/Fanconi DNA repair pathway or other defects in homologous repair will have cancers that respond to olaparib when given in combination with the DNA damaging agents, irinotecan, cisplatin, mitomycin C (ICM).
Interventions
- DRUG Cisplatin
- DRUG Irinotecan
- DRUG Mitomycin-C
- DRUG Olaparib (for levels 1 and 5)
- DRUG Olaparib (for dose level 2)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2011-01 |
| Est. Completion | 2016-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01296763
The ClinicalTrials.gov registry entry for NCT01296763 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cisplatin is the first listed.
NCT01296763 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01296763 about?
NCT01296763 is a clinical study titled "Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer". Patients whose pancreatic cancers have defects in the BRCA/Fanconi DNA repair pathway or other defects in homologous repair will have cancers that respond to olaparib when given in combination with the DNA damaging agents, irinotecan, cisplatin, mitomycin C (ICM).
What is the current status of trial NCT01296763?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2011-01. Estimated completion is 2016-02.
What interventions are being tested in trial NCT01296763?
The interventions under investigation include: Cisplatin (DRUG), Irinotecan (DRUG), Mitomycin-C (DRUG), Olaparib (for levels 1 and 5) (DRUG), Olaparib (for dose level 2) (DRUG).
Who is sponsoring clinical trial NCT01296763?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.